West Pharmaceutical Services, Inc. WST

West Pharmaceutical Services, Inc. es un fabricante global en el diseño y producción de sistemas integrados de contención y entrega tecnológicamente avanzados para medicamentos inyectables y productos de atención médica. Sus productos incluyen varios envases primarios, soluciones de contención, sistemas de reconstitución y transferencia, y sistemas de entrega de medicamentos, así como fabricación por contrato, servicios de laboratorio analítico y soluciones integradas. Los segmentos de la Compañía incluyen Productos Propietarios y Productos Fabricados por Contrato. El segmento de Productos Propietarios ofrece envases, contenedores y productos de entrega de medicamentos propietarios, junto con servicios de laboratorio analítico y otros servicios integrados. El segmento de Productos Fabricados por Contrato fabrica componentes y dispositivos propiedad del cliente utilizados en sistemas quirúrgicos, diagnósticos, oftálmicos, inyectables y otros sistemas de entrega de medicamentos, así como productos de consumo.

Con 3 acciones de WST (USD 1.130,12) habrías recibido USD 2,64 en dividendos en los últimos 12 meses.

WST hizo una división de acciones (split) de 2:1 el 27 de septiembre de 2013: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 5 oct

  Reasons to Retain Doximity Stock in Your Portfolio for Now

  Doximity (DOCS) is experiencing strong clinical AI adoption with active workflow prescribers up 30% year-over-year and AI Scribe users growing 10-fold, validating its AI capabilities through independent studies. However, the company faces headwinds from modest overall revenue growth (7% YoY), declining gross margins (88% from 91%) due to elevated AI infrastructure costs, and a constrained pharma advertising market. While AI is opening new revenue opportunities, investors await evidence that AI monetization can materially accelerate consolidated growth.

  

• Zacks Investment Research 30 sept

  Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care

  Smith+Nephew (SNN) launched the EVOS PELVIC Plating System to expand its orthopedic trauma portfolio into pelvic and acetabular fracture management. The system features dedicated plates, cannulated screws, and specialized instruments designed to improve surgical efficiency. The global pelvic trauma market is projected to grow from $2.81 billion in 2025 to $4.79 billion by 2034 at a 6.1% CAGR, driven by increased high-energy fractures and wider adoption of surgical fixation protocols.

  

• Zacks Investment Research 23 sept

  Veeva Unveils Falcon Router to Streamline Biopharma Case Routing

  Veeva Systems announced the launch of Falcon Router, an AI-powered agentic solution designed to automate the intake and routing of safety, quality, and medical cases for biopharma companies. The solution, available for early adoption in January 2027, will integrate with Veeva's Safety, QMS, and MedInquiry platforms to reduce manual workloads and improve compliance workflows. The announcement reinforces Veeva's AI strategy focused on workflow automation within its Vault ecosystem.

  

• Zacks Investment Research 21 sept

  Reasons to Hold Hinge Health Stock in Your Portfolio for Now

  Hinge Health (HNGE) raised its 2026 revenue guidance to $856-$860M following a 53% Q2 revenue jump to $212.8M. The company is expanding beyond its core MSK platform into Migraine Care (450 clients, 5M lives) and acquiring Cylinder Health for $105M to accelerate GI expansion. While growth prospects remain strong with a 30.6% expected growth rate, continued product investments and integration costs could temper margin expansion.

  

• Zacks Investment Research 18 sept

  Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC

  Avantor has expanded its RIM single-use bioprocessing portfolio across the Asia Pacific region with local manufacturing in China. The expansion aims to improve supply reliability and customization for regional biopharma customers. The company's Bioscience & Medtech Products segment showed double-digit order growth and a 1.1x book-to-bill ratio in Q2 2026, supporting long-term bioprocessing growth.